Pasireotide companion diagnostic - OctreoPharm

Drug Profile

Pasireotide companion diagnostic - OctreoPharm

Alternative Names: 68Ga-pasireotide tetraxetan; DOTA-SOM; Gallium-68-pasireotide tetraxetan; OPS 101

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OctreoPharm Sciences
  • Class Cyclic peptides; Imaging agents; Macrocyclic compounds; Oligopeptides; Peptidomimetics; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity No

Highest Development Phases

  • No development reported Neuroendocrine tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neuroendocrine-tumours(Diagnosis) in Germany (Parenteral)
  • 27 Oct 2011 Preclinical trials in Neuroendocrine tumours (diagnosis) in Germany (Parenteral)
  • 27 Oct 2011 Pasireotide companion diagnostic receives Orphan Drug status for Neuroendocrine tumours (diagnosis) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top